Haleon invests USD 224M in new India oral health manufacturing facility

The facility is expected to open in early 2028, with supply commencing the following year.

INDIA – Haleon, the consumer health company formerly known as GSK Consumer Healthcare, has announced a major £175 million (USD 224.4 million) investment to expand its operations in Madhya Pradesh, India.

This new site represents a milestone in Haleon’s “Win as One” strategy, which prioritizes unlocking growth, driving productivity, and transforming company culture.

By strengthening its in-house supply chain capabilities, Haleon will become more resilient and better equipped to adapt quickly to evolving consumer needs. 

The investment reflects a clear structural shift toward prevention and daily self-care, with India’s consumer health market projected to exceed £23 billion by 2030. 

Brian McNamara, Haleon’s CEO, stated, “By increasing access to our trusted brands and building our capabilities on the ground, we are well-positioned to capture the significant opportunities ahead.”

“We aim to expand access to better everyday health for more than 300 million additional consumers in India, which will be key to achieving our broader ambition to reach one billion more consumers globally by 2030.”

India already ranks among Haleon’s largest oral health markets, and this investment will accelerate access to trusted, science-backed brands, including Sensodyne and Parodontax, across rural communities, with ambitions to reach over three million outlets by 2030.

Rural India, home to approximately 65% of the country’s population spread across more than 650,000 villages, faces significant unmet oral health needs. 

Dental care access remains severely limited, with a single dentist serving around 250,000 people, and as few as one in seven rural residents visiting a dentist annually, leaving many to live years with untreated tooth decay or sensitivity. 

Haleon will introduce high-quality, science-based oral health products through lower-cost, small-format toothpaste packs, including its 20-rupee (USD 0.209)Sensodyne pack, across significantly more towns and villages.

The company is also investing in “last-mile” capabilities by doubling its frontline teams on motorbikes, equipped with testing kits, samples, and diagnostic tools, and deploying them to rural areas beyond the reach of traditional retail and pharmacies. 

Simple diagnostic tools like “chill tests,” where consumers assess sensitivity by drinking cold water, help people recognize symptoms they may have endured for years and connect them with science-backed treatment for the first time. 

Haleon is further improving access through direct engagement with rural communities via education and the deployment of a network of mobile oral health literacy vans. 

These Sensodyne-branded vans transform local squares and marketplaces into community hubs for oral health awareness, sensitivity and gum health checks, and immediate access to products.

The new manufacturing facility was marked by a groundbreaking ceremony and a meeting between Haleon management and the Chief Minister of Madhya Pradesh this week. 

The facility is set to create up to 500 jobs, strengthen local capabilities, and support long-term economic development, reinforcing Haleon’s ambition to be an employer of choice in the country. 

This investment aligns with Haleon’s capital allocation priorities outlined at the company’s Capital Markets Day in 2025 and forms part of the “Build for Tomorrow” programme, which is transforming Haleon’s global supply chain to meet mid- to long-term needs through investments in key growth markets like India and China. 

The new site focuses on meeting growing demand within India while also serving other parts of Asia, strengthening local manufacturing capabilities and supply chain resilience as part of Haleon’s broader global supply chain transformation. 

Since becoming a standalone company in 2022, Haleon has redefined its presence in India by building its own dedicated end-to-end sales force and distribution network. 

Madhya Pradesh was selected due to its central location with close proximity to infrastructure, higher education, logistics, talent, and incentives.

Meanwhile, in Haleon’s new operating model announced early this year, India Subcontinent was established as a distinct Operating Unit reporting directly to the Chief Executive, reflecting the market’s scale and growth potential and reinforcing the strategic importance of this investment.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.

Newer Post

Thumbnail for Haleon invests USD 224M in new India oral health manufacturing facility

IMCD revamps Cologne technical center to meet growing formulation demand

Older Post

Thumbnail for Haleon invests USD 224M in new India oral health manufacturing facility

NtryMed expands portfolio with new face serum